A user started using topical finasteride 0.1% with Aloe Vera 0.05% on May 19, 2023, to address hair loss that began at age 27. They plan to post progress pictures every three months.
Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.
Switching from oral to topical dutasteride can cause shedding due to changes in DHT levels, and it's recommended to overlap both treatments to minimize this effect. Topical dutasteride may cause scalp irritation, and the user is considering dutasteride mesotherapy as an alternative.
The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.
A woman has been struggling with hair loss for over 12 years and is frustrated with doctors refusing to prescribe finasteride due to potential birth defects and unproven breast cancer risk. She's considering self-treatment or permanent birth control, after being offered only minoxidil, PRP therapy, and weaker natural supplements like Saw Palmetto.
The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The user is experiencing positive results in hair regrowth using a protocol that includes minoxidil, dutasteride, essential growth serum, argan oil, trioxidil shampoo, ketoconazole shampoo, and microneedling. They express hope and satisfaction with the progress after six weeks of treatment.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.